NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
28 juin 2024 16h04 HE
|
NurExone Biologic Inc
Prestigious Eye Institute Exploring New Indication for NurExone’s ExoPTEN
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
21 juin 2024 16h04 HE
|
NurExone Biologic Inc
TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company,...
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application
11 juin 2024 08h44 HE
|
NurExone Biologic Inc
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application
Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems
20 mai 2024 17h30 HE
|
Cytek Biosciences, Inc.
Cytek has announced its Enhanced Small Particle Detection Option for its Cytek Aurora™ and Cytek Northern Lights™ cell analysis systems.
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine
19 avr. 2024 16h04 HE
|
NurExone Biologic Inc
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at top European Conference on Exosomes and Regenerative Medicine
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN
22 mars 2024 17h04 HE
|
NurExone Biologic Inc
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN
NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence
15 mars 2024 16h05 HE
|
NurExone Biologic Inc
NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence
NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel
08 mars 2024 16h05 HE
|
NurExone Biologic Inc
NurExone establishing State-of-the-Art Research and Development Facility on Technion Campus in Israel
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit
01 mars 2024 16h04 HE
|
NurExone Biologic Inc
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit
NurExone’s Intellectual Property Portfolio Expands
20 févr. 2024 16h05 HE
|
NurExone Biologic Inc
NurExone's Intellectual Property portfolio is expanding to encompass processes and compositions related to exosomes in large-scale production